10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Latest (Page 2)
Setback in Lung Cancer Trial: Immunotherapy-Radiation Combo Raises Concerns
Phase 2 trial of durvalumab with radiation for NSCLC halted early due to safety and efficacy issues.
Once-Every-3-Weeks Cisplatin Triumphs in Long-Term Head and Neck Cancer Study
Long-term analysis shows superior locoregional control with high-dose cisplatin in head and neck cancer.
Gut Microbiome: A New Frontier in Predicting Immunotherapy Outcomes for Gynecologic Cancers
Study reveals gut bacteria's role in immunotherapy outcomes for cervical and endometrial cancer patients.
Immunotherapy Breakthrough: PD-1/PD-L1 Inhibitors Show Promise in Advanced Gastroesophageal Cancers
Meta-analysis reveals PD-1/PD-L1 inhibitors improve survival in advanced gastroesophageal cancers.
Subcutaneous Nivolumab: A Game-Changer for Advanced Kidney Cancer Treatment
Subcutaneous nivolumab proves noninferior to IV administration in advanced kidney cancer patients.
Cediranib/Olaparib Combo Falls Short in Platinum-Resistant Ovarian Cancer Trial
Phase II/III trial shows cediranib/olaparib not superior to chemotherapy in platinum-resistant ovarian cancer.
Pembrolizumab Boosts Disease-Free Survival in High-Risk Urothelial Carcinoma Post-Surgery
Adjuvant pembrolizumab improves disease-free survival in high-risk muscle-invasive urothelial carcinoma patients
Oral Roxadustat Shows Promise in Treating Chemotherapy-Induced Anemia
Study finds roxadustat noninferior to rHuEPO-α for chemotherapy-induced anemia in cancer patients.
Dual Checkpoint Inhibition Shows Promise in Molecularly Selected Prostate Cancer Patients
Phase II trial reveals promising results for dual immune checkpoint inhibition in specific mCRPC patients.
Immune Checkpoint Inhibitors in MS Patients: Low Relapse Risk, Promising Outlook
Study shows low relapse risk for MS patients on immune checkpoint inhibitors, suggesting safe use with precautions.
CheckMate 274: Nivolumab Boosts Survival in High-Risk Urothelial Cancer
Phase III trial shows adjuvant nivolumab improves disease-free survival in high-risk urothelial carcinoma.
T-DXd Shows Promising Results for HER2+ Breast Cancer with Brain Metastases
Large trial demonstrates T-DXd's efficacy in treating HER2+ breast cancer with brain metastases.